Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
10.92
+0.27 (2.54%)
Sep 22, 2026, 4:00 PM EDT - Market closed
Kazia Therapeutics Revenue
Kazia Therapeutics had revenue of 14.01M AUD in the half year ending December 31, 2025, with 280,273,160.00% growth. This brings the company's revenue in the last twelve months to 14.04M, up 16,040.52% year-over-year. In the fiscal year ending June 30, 2025, Kazia Therapeutics had annual revenue of 1.83M, down -26.30%.
Revenue (ttm)
14.04M AUD
Revenue Growth
+16,040.52%
P/S Ratio
118.16
Revenue / Employee
2,340,268 AUD
Employees
6
Market Cap
149.64M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.83M | -652.76K | -26.30% |
| Jun 30, 2024 | 2.48M | 2.48M | 248,088.20% |
| Jun 30, 2023 | 1.00K | -24.00K | -96.00% |
| Jun 30, 2022 | 25.00K | -15.16M | -99.84% |
| Jun 30, 2021 | 15.19M | 14.19M | 1,426.13% |
| Jun 30, 2020 | 995.00K | -470.00K | -32.08% |
| Jun 30, 2019 | 1.47M | -11.64M | -88.82% |
| Jun 30, 2018 | 13.11M | 4.30M | 48.75% |
| Jun 30, 2017 | 8.81M | 4.74M | 116.46% |
| Jun 30, 2016 | 4.07M | 1.23M | 43.24% |
| Jun 30, 2015 | 2.84M | 2.41M | 562.47% |
| Jun 30, 2014 | 429.00K | -1.30M | -75.20% |
| Jun 30, 2013 | 1.73M | -644.00K | -27.13% |
| Jun 30, 2012 | 2.37M | 52.00K | 2.24% |
| Jun 30, 2011 | 2.32M | -7.59M | -76.58% |
| Jun 30, 2010 | 9.92M | 7.41M | 295.97% |
| Jun 30, 2009 | 2.50M | -12.40M | -83.20% |
| Jun 30, 2008 | 14.91M | -5.10M | -25.49% |
| Jun 30, 2007 | 20.01M | 1.77M | 9.69% |
| Jun 30, 2006 | 18.24M | 560.00K | 3.17% |
| Jun 30, 2005 | 17.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| Caribou Biosciences | 10.04M |
| Armata Pharmaceuticals | 5.54M |
| NRx Pharmaceuticals | 3.39M |
| Korro Bio | 2.38M |
| MediciNova | 920.48K |
| Spruce Biosciences | 697.00K |
KZIA News
- 21 hours ago - Kazia Therapeutics licensee doses first patient in Phase 1b/2a paxalisib trial - TheFly
- 21 hours ago - Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders - PRNewsWire
- 13 days ago - Kazia Therapeutics announces first patient dosed in PNOC035 study - TheFly
- 13 days ago - Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer - PRNewsWire
- 21 days ago - Kazia Therapeutics price target raised to $40 from $34 at BTIG - TheFly
- 21 days ago - Kazia Therapeutics announces new preclinical, translational data on paxalisib - TheFly
- 21 days ago - Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy - PRNewsWire
- 21 days ago - Kazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer - TheFly